Aura Biosciences, Inc.(AURA)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Pending next ranking run
This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
AURA Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for Aura Biosciences, Inc. (AURA), a Healthcare sector company. AURA is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q2 2026), Aura Biosciences, Inc. reports net income of $-45.6M, free cash flow of $-32.5M. Top institutional holders of AURA by reported 13-F value include TCG Crossover Management, SUVRETTA CAPITAL MANAGEMENT, Frazier Life Sciences Management, L.P., based on the most recent SEC filings. AURA trades on the Nasdaq exchange and files with the SEC under CIK 1501796. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AURA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Aura Biosciences, Inc. directly from SEC EDGAR.
Net Income
Q2 2026
$-45.6M
Free Cash Flow
Q2 2026
$-32.5M
ROIC
Q2 2026
-61.0%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProNet Income
-22.2% YoYOperating Income
-17.3% YoYEPS (Diluted)
-0.6% YoYTotal Assets
-7.2% YoYOp. Cash Flow
-6.2% YoYFree Cash Flow
-5.1% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Net Income | $-106.2M -22.2% | $-86.9M -13.8% | $-76.4M -30.0% | $-58.8M -66.7% | $-35.3M -58.7% | $-22.2M |
| Operating Income | $-112.8M -17.3% | $-96.1M -13.1% | $-85.0M -41.0% | $-60.3M -71.0% | $-35.3M -58.7% | $-22.2M |
| EPS (Diluted) | $-1.76 -0.6% | $-1.75 +9.3% | $-1.93 +1.5% | $-1.96 +78.1% | $-8.95 | — |
| Total Assets | $169.4M -7.2% | $182.5M -28.5% | $255.1M +13.9% | $223.9M +39.9% | $160.0M +624.0% | $22.1M |
| Operating Cash Flow | $-84.7M -6.2% | $-79.8M -25.0% | $-63.8M -16.9% | $-54.6M -68.5% | $-32.4M -33.3% | $-24.3M |
| Free Cash Flow | $-85.2M -5.1% | $-81.1M -25.6% | $-64.6M -15.9% | $-55.7M -61.3% | $-34.5M -37.6% | $-25.1M |
Get alerted when AURA's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Aura Biosciences, Inc. including:
Top Institutional Holders of AURA
TCG Crossover Management, LLC
$67.7M9,533,333 shSUVRETTA CAPITAL MANAGEMENT, LLC
$51.2M7,206,217 shFrazier Life Sciences Management, L.P.
$50.4M7,100,000 shLong Focus Capital Management, LLC
$36.3M5,119,582 shBlackRock, Inc.
$33.4M4,707,674 shADAGE CAPITAL PARTNERS GP, L.L.C.
$32.9M4,640,000 shCaligan Partners LP
$30.5M4,298,248 shVANGUARD CAPITAL MANAGEMENT LLC
$29.1M4,100,342 shFCPM III SERVICES B.V.
$28.8M4,053,775 shORBIMED ADVISORS LLC
$23.7M3,333,333 sh
| Fund | Value | Shares |
|---|---|---|
| TCG Crossover Management, LLC | $67.7M | 9,533,333 |
| SUVRETTA CAPITAL MANAGEMENT, LLC | $51.2M | 7,206,217 |
| Frazier Life Sciences Management, L.P. | $50.4M | 7,100,000 |
| Long Focus Capital Management, LLC | $36.3M | 5,119,582 |
| BlackRock, Inc. | $33.4M | 4,707,674 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $32.9M | 4,640,000 |
| Caligan Partners LP | $30.5M | 4,298,248 |
| VANGUARD CAPITAL MANAGEMENT LLC | $29.1M | 4,100,342 |
| FCPM III SERVICES B.V. | $28.8M | 4,053,775 |
| ORBIMED ADVISORS LLC | $23.7M | 3,333,333 |
More Healthcare Companies
View all Healthcare →Put AURA on your watchlist
Track score changes the day Aura Biosciences, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is AURA a good stock to buy?
13F Pro's AI-powered analysis of Aura Biosciences, Inc. (AURA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for AURA are available on the AURA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. AURA is classified as a small company.
Which hedge funds own AURA?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling AURA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Aura Biosciences, Inc.'s investment landscape.